Browse > Article
http://dx.doi.org/10.3340/jkns.2015.57.2.73

Effects of Tumor Necrosis Factor Alpha Blocker Adalimumab in Experimental Spinal Cord Injury  

Borcek, Alp Ozgun (Department of Neurosurgery, Gazi University Faculty of Medicine)
Civi, Soner (Department of Neurosurgery, Medicana Private Hospital)
Ocal, Ozgur (Department of Neurosurgery, Gazi University Faculty of Medicine)
Gulbahar, Ozlem (Department of Biochemistry, Gazi University Faculty of Medicine)
Publication Information
Journal of Korean Neurosurgical Society / v.57, no.2, 2015 , pp. 73-76 More about this Journal
Abstract
Objective : Tumor necrosis factor alpha (TNF-${\alpha}$) have proven effects in pathogenesis of neuroinflammation after spinal cord injury (SCI). Current study is designed to evaluate the effects of an anti-TNF-${\alpha}$ agent, adalimumab, on spinal cord clip compression injury in rats. Methods : Thirty two male adult Wistar rats were divided into four groups (sham, trauma, infliximab, and adalimumab groups) and SCI was introduced using an aneurysm clip. Animals in treatment groups received 5 mg/kg subcutaneous adalimumab and infliximab right after the trauma. Malondialdehyde (MDA) levels were studied in traumatized spinal cord tissues 72 hours after the injury as a marker of lipid peroxidation. Results : Animals that received anti-TNF-${\alpha}$ agents are found to have significantly decreased MDA levels. MDA levels were significantly different between the trauma and infliximab groups (p<0.01) and trauma and adalimumab groups (p=0.022). There was no significant difference in neurological evaluation of the rats using Tarlov scale. Conclusion : These results suggest that, like infliximab, adalimumab has favorable effects on lipid peroxidation induced by spinal cord trauma in rats.
Keywords
Adalimumab; Spinal cord injury; Tumor necrosis factor alpha;
Citations & Related Records
Times Cited By KSCI : 1  (Citation Analysis)
연도 인용수 순위
1 Bracken MB : Methylprednisolone and acute spinal cord injury : an update of the randomized evidence. Spine (Phila Pa 1976) 26 (24 Suppl) : S47-S54, 2001   DOI
2 Diak P, Siegel J, La Grenade L, Choi L, Lemery S, McMahon A : Tumor necrosis factor alpha blockers and malignancy in children : forty-eight cases reported to the Food and Drug Administration. Arthritis Rheum 62 : 2517-2524, 2010   DOI
3 Kurt G, Cemil B, Borcek AO, Borcek P, Akyurek N, Sepici A, et al. : Infliximab administration reduces neuronal apoptosis on the optic pathways in a rabbit hydrocephalus model : a preliminary report. Br J Neurosurg 24 : 275-279, 2010
4 Wang CX, Nuttin B, Heremans H, Dom R, Gybels J : Production of tumor necrosis factor in spinal cord following traumatic injury in rats. J Neuroimmunol 69 : 151-156, 1996   DOI
5 Reinisch W, Sandborn WJ, Hommes DW, D'Haens G, Hanauer S, Schreiber S, et al. : Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis : results of a randomised controlled trial. Gut 60 : 780-787, 2011   DOI
6 Beattie MS, Hermann GE, Rogers RC, Bresnahan JC : Cell death in models of spinal cord injury. Prog Brain Res 137 : 37-47, 2002   DOI
7 Balentine JD : Pathology of experimental spinal cord trauma. I. The necrotic lesion as a function of vascular injury. Lab Invest 39 : 236-253, 1978
8 Balentine JD : Pathology of experimental spinal cord trauma. II. Ultrastructure of axons and myelin. Lab Invest 39 : 254-266, 1978
9 Bayrakli F, Balaban H, Ozum U, Duger C, Topaktas S, Kars HZ : Etanercept treatment enhances clinical and neuroelectrophysiological recovery in partial spinal cord injury. Eur Spine J 21 : 2588-2593, 2012   DOI
10 Bethea JR, Nagashima H, Acosta MC, Briceno C, Gomez F, Marcillo AE, et al. : Systemically administered interleukin-10 reduces tumor necrosis factor-alpha production and significantly improves functional recovery following traumatic spinal cord injury in rats. J Neurotrauma 16 : 851-863, 1999   DOI
11 Bracken MB, Collins WF, Freeman DF, Shepard MJ, Wagner FW, Silten RM, et al. : Efficacy of methylprednisolone in acute spinal cord injury. JAMA 251 : 45-52, 1984   DOI
12 Blight AR : Macrophages and inflammatory damage in spinal cord injury. J Neurotrauma 9 Suppl 1 : S83-S91, 1992
13 Bracken MB : Methylprednisolone in the management of acute spinal cord injuries. Med J Aust 153 : 368, 1990
14 Bracken MB : Steroids for acute spinal cord injury. Cochrane Database Syst Rev 1 : CD001046, 2012
15 Bracken MB, Shepard MJ, Collins WF, Holford TR, Young W, Baskin DS, et al. : A randomized, controlled trial of methylprednisolone or naloxone in the treatment of acute spinal-cord injury. Results of the Second National Acute Spinal Cord Injury Study. N Engl J Med 322 : 1405-1411, 1990   DOI
16 Bracken MB, Shepard MJ, Hellenbrand KG, Collins WF, Leo LS, Freeman DF, et al. : Methylprednisolone and neurological function 1 year after spinal cord injury. Results of the National Acute Spinal Cord Injury Study. J Neurosurg 63 : 704-713, 1985   DOI
17 Burmester GR, Mease P, Dijkmans BA, Gordon K, Lovell D, Panaccione R, et al. : Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseases. Ann Rheum Dis 68 : 1863-1869, 2009   DOI
18 Burness CB, Keating GM : Adalimumab : a review of its use in the treatment of patients with ulcerative colitis. BioDrugs 27 : 247-262, 2013   DOI
19 Caminero A, Comabella M, Montalban X : Tumor necrosis factor alpha (TNF-${\alpha}$), anti-TNF-${\alpha}$ and demyelination revisited : an ongoing story. J Neuroimmunol 234 : 1-6, 2011   DOI
20 Carlson SL, Parrish ME, Springer JE, Doty K, Dossett L : Acute inflammatory response in spinal cord following impact injury. Exp Neurol 151 : 77-88, 1998   DOI
21 Catala A : Lipid peroxidation of membrane phospholipids generates hydroxy-alkenals and oxidized phospholipids active in physiological and/ or pathological conditions. Chem Phys Lipids 157 : 1-11, 2009   DOI
22 Ducker TB, Kindt GW, Kempf LG : Pathological findings in acute experimental spinal cord trauma. J Neurosurg 35 : 700-708, 1971   DOI
23 Emmez H, Borcek AO, Kaymaz M, Kaymaz F, Durdag E, Civi S, et al. : Neuroprotective effects of gabapentin in experimental spinal cord injury. World Neurosurg 73 : 729-734, 2010   DOI
24 Fleming JC, Norenberg MD, Ramsay DA, Dekaban GA, Marcillo AE, Saenz AD, et al. : The cellular inflammatory response in human spinal cords after injury. Brain 129 (Pt 12) : 3249-3269, 2006   DOI
25 Grotto D, Maria LS, Valentini J, Paniz C, Schmitt G, Garcia SC, et al. : Importance of the lipid peroxidation biomarkers and methodological aspects for malondialdehyde quantification. Quim Nova 32 : 169-174, 2009   DOI
26 Guadagno J, Xu X, Karajgikar M, Brown A, Cregan SP : Microglia-derived TNF${\alpha}$ induces apoptosis in neural precursor cells via transcriptional activation of the Bcl-2 family member Puma. Cell Death Dis 4 : e538, 2013   DOI
27 Guven C, Borcek AO, Cemil B, Kurt G, Yildirim Z, Ucankus NL, et al. : Neuroprotective effects of infliximab in experimental spinal cord ischemic injury. J Clin Neurosci 17 : 1563-1567, 2010   DOI
28 Hall ED : Inhibition of lipid peroxidation in CNS trauma. J Neurotrauma 8 Suppl 1 : S31-S40; discussion S41, 1991
29 Hall ED, Braughler JM : Free radicals in CNS injury. Res Publ Assoc Res Nerv Ment Dis 71 : 81-105, 1993
30 Hamada Y, Ikata T, Katoh S, Nakauchi K, Niwa M, Kawai Y, et al. : Involvement of an intercellular adhesion molecule 1-dependent pathway in the pathogenesis of secondary changes after spinal cord injury in rats. J Neurochem 66 : 1525-1531, 1996
31 Harrington JF, Messier AA, Levine A, Szmydynger-Chodobska J, Chodobski A : Shedding of tumor necrosis factor type 1 receptor after experimental spinal cord injury. J Neurotrauma 22 : 919-928, 2005   DOI
32 Kaymakcalan Z, Sakorafas P, Bose S, Scesney S, Xiong L, Hanzatian DK, et al. : Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor. Clin Immunol 131 : 308-316, 2009   DOI
33 Klebanoff SJ, Vadas MA, Harlan JM, Sparks LH, Gamble JR, Agosti JM, et al. : Stimulation of neutrophils by tumor necrosis factor. J Immunol 136 : 4220-4225, 1986
34 Kurt G, Ergun E, Cemil B, Borcek AO, Börcek P, Gulbahar O, et al. : Neuroprotective effects of infliximab in experimental spinal cord injury. Surg Neurol 71 : 332-336; discussion 336, 2009   DOI
35 Kwon BK, Okon E, Hillyer J, Mann C, Baptiste D, Weaver LC, et al. : A systematic review of non-invasive pharmacologic neuroprotective treatments for acute spinal cord injury. J Neurotrauma 28 : 1545-1588, 2011   DOI
36 Mihara M, Uchiyama M : Determination of malonaldehyde precursor in tissues by thiobarbituric acid test. Anal Biochem 86 : 271-278, 1978   DOI
37 Papakostas JC, Matsagas MI, Toumpoulis IK, Malamou-Mitsi VD, Pappa LS, Gkrepi C, et al. : Evolution of spinal cord injury in a porcine model of prolonged aortic occlusion. J Surg Res 133 : 159-166, 2006   DOI
38 Sekhon LH, Fehlings MG : Epidemiology, demographics, and pathophysiology of acute spinal cord injury. Spine (Phila Pa 1976) 26 (24 Suppl): S2-S12, 2001   DOI
39 Yu SH, Cho DC, Kim KT, Nam KH, Cho HJ, Sung JK : The neuroprotective effect of treatment of valproic Acid in acute spinal cord injury. J Korean Neurosurg Soc 51 : 191-198, 2012   DOI
40 Tang X, Wang Y, Zhou S, Qian T, Gu X : Signaling pathways regulating dose-dependent dual effects of TNF-${\alpha}$ on primary cultured Schwann cells. Mol Cell Biochem 378 : 237-246, 2013   DOI